Related Experiment Videos
Oxitropium bromide, a new anticholinergic bronchodilator.
Annals of Allergy
|March 1, 1986
Summary
Oxitropium bromide effectively bronchodilates in COPD patients, showing rapid onset and long-lasting effects. This anticholinergic agent demonstrated significant improvements in lung function without adverse cardiovascular effects.
Area of Science:
- Pharmacology
- Pulmonology
- Respiratory Medicine
Background:
- Oxitropium bromide (OB) is an anticholinergic bronchodilator.
- Chronic Obstructive Pulmonary Disease (COPD) requires effective bronchodilator therapy.
Purpose of the Study:
- To evaluate the bronchodilating properties and dose-response of Oxitropium bromide in COPD patients.
- To compare OB's efficacy against isoproterenol and placebo.
Main Methods:
- Double-blind, placebo-controlled study involving 14 COPD patients.
- Administration of five doses of OB, isoproterenol (ISO), and placebo via metered-dose inhaler.
- Assessment of pulmonary function (flow-volume loops, airways resistance), blood pressure, and pulse rate for eight hours.
Main Results:
- OB demonstrated a rapid onset of bronchodilation within five minutes and a duration of action of at least eight hours.
- Significant dose-dependent improvements in FEV1, forced vital capacity, and specific airways conductance (SGAW) were observed compared to placebo.
- Higher doses of OB (100-400 micrograms) showed superior efficacy to ISO for FEV1 and SGAW.
- No significant adverse effects on pulse, blood pressure, or ECG were noted.
Conclusions:
- Oxitropium bromide is an effective bronchodilator for COPD patients.
- OB offers a favorable safety profile with rapid onset and prolonged duration of action.
- OB represents a valuable therapeutic option for managing COPD symptoms.